PriceTargets.com logo

Nevro - NVRO Stock Price Target and Predictions

  • Consensus Rating: Reduce
  • Consensus Price Target: $5.36
  • Forecasted Upside: -8.29%
  • Number of Analysts: 12
  • Breakdown:
  • 2 Sell Ratings
  • 9 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$5.85 As of 04/2/2025 08:56 PM ET
▲ +0.006 (0.10%)

This chart shows the closing price for NVRO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Nevro Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NVRO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NVRO

Analyst Price Target is $5.36
▼ -8.29% Downside Potential
This price target is based on 12 analysts offering 12 month price targets for Nevro in the last 3 months. The average price target is $5.36, with a high forecast of $7.00 and a low forecast of $4.00. The average price target represents a -8.29% upside from the last price of $5.85.

This chart shows the closing price for NVRO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Reduce

The current consensus among 12 polled investment analysts is to reduce stock in Nevro. This rating has held steady since May 2024, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 7 hold ratings
  • 1 sell ratings
Ratings as of
11/21/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 10 hold ratings
  • 1 sell ratings
Ratings as of
2/19/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 11 hold ratings
  • 1 sell ratings
Ratings as of
5/19/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 11 hold ratings
  • 3 sell ratings
Ratings as of
8/17/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 11 hold ratings
  • 3 sell ratings
Ratings as of
11/15/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 11 hold ratings
  • 2 sell ratings
Ratings as of
2/13/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 9 hold ratings
  • 2 sell ratings
Ratings as of
4/14/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 9 hold ratings
  • 2 sell ratings
Ratings as of
5/14/2025

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 9 hold ratings
  • 2 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
2/10/2025Jefferies Financial GroupUpgradeUnderperform ➝ Hold$4.50 ➝ $5.85
2/7/2025Canaccord Genuity GroupBoost TargetHold ➝ Hold$4.00 ➝ $5.85
2/7/2025Piper SandlerUpgradeNeutral ➝ Overweight$6.00 ➝ $5.85
12/18/2024Truist FinancialLower TargetHold ➝ Hold$7.00 ➝ $4.70
12/11/2024CitigroupLower TargetNeutral ➝ Neutral$6.00 ➝ $5.00
12/11/2024Wells Fargo & CompanyLower TargetEqual Weight ➝ Equal Weight$5.00 ➝ $4.00
12/9/2024Canaccord Genuity GroupLower TargetHold ➝ Hold$7.00 ➝ $4.00
12/3/2024Wells Fargo & CompanyInitiated CoverageStrong Sell ➝ Equal Weight$5.00
12/2/2024Morgan StanleyDowngradeEqual Weight ➝ Underweight$9.00 ➝ $4.00
11/12/2024JMP SecuritiesReiterated RatingMarket Perform
11/12/2024Canaccord Genuity GroupLower TargetHold ➝ Hold$8.00 ➝ $7.00
11/12/2024Royal Bank of CanadaReiterated RatingSector Perform ➝ Sector Perform$7.00 ➝ $7.00
11/12/2024Piper SandlerLower TargetUnderweight ➝ Underweight$7.00 ➝ $6.00
11/12/2024Robert W. BairdBoost TargetNeutral ➝ Neutral$5.00 ➝ $6.00
10/1/2024CitigroupLower TargetNeutral ➝ Neutral$6.89 ➝ $6.00
8/9/2024CitigroupUpgradeSell ➝ Neutral$6.89
8/8/2024Truist FinancialLower TargetHold ➝ Hold$10.00 ➝ $5.50
8/8/2024Wolfe ResearchUpgradeUnderperform ➝ Peer Perform
8/7/2024Royal Bank of CanadaLower TargetSector Perform ➝ Sector Perform$16.00 ➝ $7.00
8/7/2024Robert W. BairdLower TargetNeutral ➝ Neutral$11.00 ➝ $8.00
8/7/2024Piper SandlerLower TargetUnderweight ➝ Underweight$12.00 ➝ $7.00
8/7/2024JMP SecuritiesDowngradeOutperform ➝ Market Perform
8/7/2024JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight
8/7/2024Wells Fargo & CompanyDowngradeEqual Weight ➝ Underweight$13.00 ➝ $5.50
7/16/2024Truist FinancialLower TargetHold ➝ Hold$11.00 ➝ $10.00
7/15/2024Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$14.00 ➝ $9.00
7/10/2024CitigroupLower TargetSell ➝ Sell$9.00 ➝ $8.20
5/22/2024CitigroupDowngradeNeutral ➝ Sell$13.50 ➝ $9.00
5/8/2024Canaccord Genuity GroupLower TargetHold ➝ Hold$17.00 ➝ $11.00
5/8/2024Wells Fargo & CompanyLower TargetEqual Weight ➝ Equal Weight$14.00 ➝ $13.00
5/8/2024Piper SandlerLower TargetUnderweight ➝ Underweight$15.00 ➝ $12.00
4/15/2024Royal Bank of CanadaLower TargetSector Perform ➝ Sector Perform$18.00 ➝ $16.00
4/11/2024MizuhoLower TargetNeutral ➝ Neutral$20.00 ➝ $16.00
4/8/2024Wells Fargo & CompanyLower TargetEqual Weight ➝ Equal Weight$17.00 ➝ $14.00
4/3/2024CitigroupLower TargetNeutral ➝ Neutral$18.00 ➝ $16.00
2/22/2024Robert W. BairdLower TargetNeutral ➝ Neutral$23.00 ➝ $19.00
2/22/2024Wells Fargo & CompanyLower TargetEqual Weight ➝ Equal Weight$20.00 ➝ $17.00
2/22/2024OppenheimerDowngradeOutperform ➝ Market Perform
1/12/2024Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$23.00 ➝ $20.00
12/22/2023Truist FinancialBoost TargetHold ➝ Hold$22.00 ➝ $23.00
12/21/2023Canaccord Genuity GroupReiterated RatingBuy ➝ Hold$23.00
12/21/2023Canaccord Genuity GroupDowngradeBuy ➝ Hold$23.00
12/1/2023Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$23.00
11/3/2023Truist FinancialLower TargetHold ➝ Hold$18.50 ➝ $17.00
11/2/2023Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$23.00 ➝ $18.00
11/2/2023Piper SandlerLower TargetUnderweight ➝ Underweight$24.00 ➝ $15.00
11/2/2023JPMorgan Chase & Co.Lower TargetNeutral ➝ Neutral$23.00 ➝ $18.00
8/21/2023CitigroupLower TargetNeutral ➝ Neutral$24.00 ➝ $21.00
8/17/2023Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$33.00
8/3/2023Truist FinancialLower TargetHold ➝ Hold$27.00 ➝ $25.00
8/2/2023OppenheimerLower TargetOutperform ➝ Outperform$40.00 ➝ $35.00
8/2/2023Wells Fargo & CompanyLower TargetEqual Weight ➝ Equal Weight$27.00 ➝ $23.00
8/2/2023Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$29.00 ➝ $23.00
8/2/2023JPMorgan Chase & Co.Lower TargetNeutral ➝ Neutral$28.00 ➝ $23.00
8/2/2023Canaccord Genuity GroupLower TargetBuy ➝ Buy$68.00 ➝ $57.00
8/2/2023Royal Bank of CanadaLower TargetOutperform ➝ Outperform$39.00 ➝ $33.00
8/2/2023Robert W. BairdLower TargetNeutral ➝ Neutral$26.00 ➝ $23.00
8/2/2023JMP SecuritiesLower TargetOutperform ➝ Outperform$75.00 ➝ $40.00
7/19/2023Truist FinancialLower TargetHold$30.00 ➝ $27.00
7/18/2023Robert W. BairdInitiated CoverageNeutral$26.00
7/17/2023MizuhoLower Target$40.00 ➝ $30.00
6/28/2023JPMorgan Chase & Co.Lower Target$40.00 ➝ $28.00
6/7/2023CitigroupLower Target$37.00 ➝ $27.00
6/6/2023Truist FinancialLower Target$32.00 ➝ $30.00
5/31/2023Royal Bank of CanadaInitiated CoverageOutperform$40.00
5/18/2023Truist FinancialLower Target$40.00 ➝ $32.00
5/15/2023OppenheimerUpgradeMarket Perform ➝ Outperform$40.00
4/27/2023Piper SandlerLower Target$37.00 ➝ $34.00
4/17/2023Truist FinancialLower TargetHold$42.00 ➝ $40.00
4/13/2023MizuhoInitiated CoverageNeutral$40.00
2/6/2023Canaccord Genuity GroupBoost TargetBuy$67.00 ➝ $72.00
1/26/2023Piper SandlerLower TargetUnderweight$38.00 ➝ $37.00
1/17/2023CitigroupDowngradeBuy ➝ Neutral$40.00
1/11/2023Wells Fargo & CompanyLower TargetEqual Weight$43.00 ➝ $37.00
1/6/2023Morgan StanleyLower TargetEqual Weight$49.00 ➝ $46.00
1/6/2023Piper SandlerDowngradeNeutral ➝ Underweight$42.00 ➝ $38.00
12/20/2022Truist FinancialLower TargetHold$45.00 ➝ $41.00
12/20/2022Canaccord Genuity GroupUpgradeHold ➝ Buy$41.00 ➝ $67.00
12/12/2022Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$66.00 ➝ $43.00
11/3/2022JPMorgan Chase & Co.Lower TargetNeutral$50.00 ➝ $40.00
11/3/2022Piper SandlerLower TargetNeutral$45.00 ➝ $42.00
11/2/2022William BlairReiterated RatingMarket Perform
10/12/2022Jefferies Financial GroupInitiated CoverageUnderperform$31.00
10/11/2022Morgan StanleyLower TargetEqual Weight$54.00 ➝ $49.00
8/4/2022Morgan StanleyLower TargetEqual Weight$55.00 ➝ $54.00
8/4/2022Wells Fargo & CompanyLower TargetOverweight$90.00 ➝ $86.00
8/4/2022Piper SandlerLower TargetNeutral$64.00 ➝ $45.00
7/22/2022Truist FinancialLower Target$45.00
6/7/2022Morgan StanleyLower TargetEqual Weight$74.00 ➝ $55.00
5/26/2022JMP SecuritiesLower TargetMarket Outperform$125.00 ➝ $95.00
5/17/2022CitigroupLower Target$78.00 ➝ $68.00
5/5/2022CitigroupUpgradeNeutral ➝ Buy$78.00
5/5/2022Piper SandlerLower Target$65.00 ➝ $64.00
4/5/2022Wolfe ResearchInitiated CoverageUnderperform$64.00
3/2/2022Bank of AmericaInitiated CoverageUnderperform ➝ Underperform
2/25/2022Morgan StanleyLower TargetEqual Weight$100.00 ➝ $76.00
2/25/2022Canaccord Genuity GroupLower TargetHold ➝ Hold$97.00 ➝ $72.00
2/24/2022Leerink PartnersLower TargetOutperform$105.00 ➝ $85.00
2/24/2022Wells Fargo & CompanyLower TargetOverweight$116.00 ➝ $90.00
2/24/2022Piper SandlerLower TargetNeutral$92.00 ➝ $65.00
1/12/2022Canaccord Genuity GroupLower TargetHold ➝ Hold$118.00 ➝ $97.00
1/7/2022Morgan StanleyDowngradeOverweight ➝ Equal Weight$140.00 ➝ $100.00
1/3/2022Piper SandlerLower Target$115.00 ➝ $90.00
12/21/2021Truist FinancialLower TargetHold$105.00 ➝ $95.00
12/6/2021Wells Fargo & CompanyUpgradeEqual Weight ➝ Overweight$116.00
11/19/2021Leerink PartnersReiterated RatingBuy$128.00
11/9/2021Truist FinancialDowngradeBuy ➝ Hold$165.00 ➝ $105.00
11/9/2021Wells Fargo & CompanyLower TargetEqual Weight$122.00 ➝ $116.00
11/9/2021CitigroupLower TargetNeutral$125.00 ➝ $120.00
11/9/2021Piper SandlerLower TargetIn-Line ➝ Neutral$125.00 ➝ $115.00
11/9/2021Leerink PartnersLower TargetOutperform$147.00 ➝ $128.00
8/5/2021Truist FinancialLower TargetPositive ➝ Buy$205.00 ➝ $165.00
8/5/2021Morgan StanleyLower TargetOverweight$199.00 ➝ $150.00
8/5/2021Leerink PartnersLower TargetOutperform$210.00 ➝ $147.00
8/5/2021JMP SecuritiesLower TargetOutperform$190.00 ➝ $160.00
8/5/2021William BlairDowngradeOutperform ➝ Market Perform
8/5/2021Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$122.00
8/5/2021CitigroupDowngradeBuy ➝ Neutral$198.00 ➝ $125.00
8/5/2021Piper SandlerDowngradeOverweight ➝ Neutral$200.00 ➝ $125.00
7/9/2021Redburn PartnersDowngradeBuy ➝ Neutral
7/6/2021Robert W. BairdDowngradeOutperform ➝ Neutral$188.00 ➝ $150.00
7/2/2021Leerink PartnersReiterated RatingBuy
6/28/2021Wells Fargo & CompanyLower TargetOverweight$215.00 ➝ $202.00
6/28/2021Robert W. BairdLower TargetOutperform$200.00 ➝ $188.00
6/28/2021Piper SandlerBoost TargetOverweight$190.00 ➝ $200.00
3/4/2021Leerink PartnersReiterated RatingBuy
2/26/2021Morgan StanleyBoost TargetOverweight$192.00 ➝ $199.00
2/2/2021Piper SandlerInitiated CoverageOverweight$190.00
1/19/2021Leerink PartnersBoost TargetPositive ➝ Outperform$190.00 ➝ $210.00
1/6/2021Truist FinancialBoost Target$175.00 ➝ $205.00
1/5/2021Robert W. BairdBoost TargetOutperform$180.00 ➝ $200.00
1/4/2021Wells Fargo & CompanyBoost TargetOverweight$177.00 ➝ $215.00
12/31/2020GuggenheimBoost TargetBuy$190.00 ➝ $205.00
12/15/2020Morgan StanleyBoost TargetOverweight$161.00 ➝ $192.00
11/11/2020JMP SecuritiesReiterated RatingOutperform$150.00 ➝ $190.00
11/6/2020Morgan StanleyBoost TargetOverweight$150.00 ➝ $161.00
10/22/2020GuggenheimInitiated CoverageBuy$190.00
10/21/2020OTR GlobalUpgradePositive
10/12/2020Leerink PartnersBoost TargetOutperform$165.00 ➝ $175.00
9/1/2020Robert W. BairdInitiated CoverageOutperform$160.00
8/6/2020Morgan StanleyBoost TargetOverweight$145.00 ➝ $150.00
8/6/2020Wells Fargo & CompanyBoost TargetOverweight$141.00 ➝ $153.00
8/6/2020Leerink PartnersBoost TargetOutperform$140.00 ➝ $165.00
8/6/2020CitigroupBoost TargetBuy$137.00 ➝ $160.00
8/5/2020OppenheimerInitiated CoverageHold
6/18/2020Morgan StanleyBoost Target$135.00 ➝ $145.00
6/18/2020CitigroupBoost TargetOverweight$135.00 ➝ $145.00
6/8/2020UBS GroupUpgradeSell ➝ Neutral$100.00 ➝ $132.00
6/4/2020SunTrust BanksReiterated RatingBuy$135.00
(Data available from 5/14/2020 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 6 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/16/2024
  • 7 very positive mentions
  • 21 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
11/15/2024
  • 7 very positive mentions
  • 8 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
12/15/2024
  • 3 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
1/14/2025
  • 5 very positive mentions
  • 22 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
2/13/2025
  • 2 very positive mentions
  • 15 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
3/15/2025
  • 2 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
4/14/2025
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/14/2025

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Nevro logo
Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems. It also offers Senza HFX iQ platform, that includes HFX iQ implantable pulse generator, HFX trial stimulator, and HFX iQ patient remote, as well as HFX App, a patient remote control and the wireless trialing system; and provides sacroiliac joint fusion devices under NevroV1, NevroFix, and NevroPro brands. In addition, the company offers surpass surgical and percutaneous leads. It sells its products through its direct sales force, and a network of sales agents and independent distributors. The company was incorporated in 2006 and is headquartered in Redwood City, California.
Read More

Today's Range

Now: $5.85
Low: $5.84
High: $5.86

50 Day Range

MA: $5.83
Low: $5.78
High: $5.85

52 Week Range

Now: $5.85
Low: $3.17
High: $11.65

Volume

753,602 shs

Average Volume

760,127 shs

Market Capitalization

$224.32 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.81

Frequently Asked Questions

What sell-side analysts currently cover shares of Nevro?

The following Wall Street research analysts have issued stock ratings on Nevro in the last year: Canaccord Genuity Group Inc., Citigroup Inc., Jefferies Financial Group Inc., JMP Securities, JPMorgan Chase & Co., Morgan Stanley, Piper Sandler, Robert W. Baird, Royal Bank of Canada, StockNews.com, Truist Financial Co., Wells Fargo & Company, and Wolfe Research.
View the latest analyst ratings for NVRO.

What is the current price target for Nevro?

0 Wall Street analysts have set twelve-month price targets for Nevro in the last year. Their average twelve-month price target is $5.36, suggesting a possible downside of 8.3%. Royal Bank of Canada has the highest price target set, predicting NVRO will reach $7.00 in the next twelve months. Wells Fargo & Company has the lowest price target set, forecasting a price of $4.00 for Nevro in the next year.
View the latest price targets for NVRO.

What is the current consensus analyst rating for Nevro?

Nevro currently has 2 sell ratings, 9 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Reduce."
View the latest ratings for NVRO.

What other companies compete with Nevro?

Other companies that are similar to Nevro include SI-BONE, Embecta, Iradimed, CeriBell and Beta Bionics. Learn More about companies similar to Nevro.

How do I contact Nevro's investor relations team?

Nevro's physical mailing address is 1800 BRIDGE PARKWAY, REDWOOD CITY CA, 94065. The medical equipment provider's listed phone number is (650) 251-0005 and its investor relations email address is [email protected]. The official website for Nevro is www.nevro.com. Learn More about contacing Nevro investor relations.